As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...
Zacks Investment Research on MSN
BD expands BD MAX with IVDR-approved VIASURE tests in Europe
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the expansion of its respiratory and sexually ...
TipRanks on MSN
Becton Dickinson announces expansion of BD MAX system menu
BD announced the expansion of its respiratory and sexually transmitted infection diagnostics offerings in Europe following In Vitro Diagnostic ...
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...
10don MSN
Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector
On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback